Versant Venture Management, LLC
In its 13F for Q1 2024 (holdings as of March 31, 2024, filed May 3, 2024), Versant Venture Management, LLC reported 7 stock positions worth $103.1 million. Its top holding was Crispr Therapeutics (CRSP) at 32.9% of the portfolio, followed by Skye Bioscience (SKYE, 30.4%) and Repare Therapeutics (RPTX, 12.1%). Compared with Q4 2023, it opened 1 new position, sold out of 1 and reduced 1. The biggest buy was a new position in Skye Bioscience (SKYE) and the biggest sale an exit from Rayzebio (RYZB).
- Most Recent 13F
- Q2 2026
- Location
- San Francisco, CA
- CIK
- 0001560009
- Portfolio Value
- $103.1M (Q1 2024)
- SEC Filing
- 0000950123-24-003797 ↗ filed May 3, 2024
Holdings Value
Holdings 7 stocks · $103.1M
| CRSP Crispr Therapeutics AG | 32.95% | 498,558 | $34.0M | No change |
| SKYE Skye Bioscience Inc. | 30.45% | 2,007,702 | $31.4M | New |
| RPTX Repare Therapeutics Inc. | 12.09% | 2,646,657 | $12.5M | No change |
| GRITSTONE BIO INC | 8.87% | 3,561,150 | $9.2M | No change |
| ADVM Adverum Biotechnologies Inc. | 6.95% | 506,822 | $7.2M | Reduce -90.0% |
| PASG Passage Bio Inc. | 6.49% | 4,959,769 | $6.7M | No change |
| ALGS Aligos Therapeutics Inc. | 2.20% | 2,320,381 | $2.3M | No change |
Portfolio Sells Q4 2023 → Q1 2024
Portfolio Buys Q4 2023 → Q1 2024
| SKYE Skye Bioscience Inc. | New | 30.45% | +30.45 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 8 | $162.6M | GLUE, IPSC, JBIO, LENZ, CTNM |
| Q1 2026 | 8 | $141.4M | GLUE, IPSC, LENZ, JBIO, CTNM |
| Q4 2025 | 7 | $151.1M | GLUE, LENZ, JBIO, CRSP, CTNM |
| Q3 2025 | 9 | $212.5M | LENZ, GLUE, JBIO, CRSP, SKYE |
| Q2 2025 | 8 | $82.1M | GLUE, CRSP, JBIO, SKYE, RPTX |
| Q1 2025 | 7 | $60.2M | GLUE, CRSP, CTNM, SKYE, RPTX |
| Q4 2024 | 7 | $86.7M | GLUE, CRSP, CTNM, SKYE, RPTX |
| Q3 2024 | 6 | $63.6M | CRSP, CTNM, RPTX, SKYE, ADVM |
| Q2 2024 | 8 | $77.3M | CRSP, CTNM, SKYE, RPTX, ADVM |
| Q1 2024 | 7 | $103.1M | CRSP, SKYE, RPTX, GRITSTONE BIO INC, ADVM |